Medivation Submits NDA For Enzalutamide

Medivation: Interim Analysis For PREVAIL Trial Expected To Occur In 2013

Trade MDVN now with

5/21/2012 8:34 PM ET

Medivation, Inc. (MDVN: Quote) said Monday that it has submitted a New Drug Application to the U.S. Food and Drug Administration for enzalutamide, formerly MDV3100.

The compound has been studied in patients with castration-resistant prostate cancer who have received docetaxel therapy.

The FDA is expected to determine within 60 days whether to accept the filing for review.

Medivation said it has requested Priority Review, a designation given to drugs that offer a significant improvement in treatment or provide treatment where no satisfactory alternative therapy exists.

If a Priority Review is granted, the FDA goal for completing a review is six months.

Click here to receive FREE breaking news email alerts for MEDIVATION INC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 78 Articles

Editors Pick

China May Leading Index Signals Weaker Economic Growth Ahead

A leading indicator of Chinese economic activity rose marginally in May and at a slower pace than a month earlier, suggesting more sluggish growth for the overall economy in the months ahead. The Conference Board said that its leading economic indicator rose 0.3 percent month-on-month in May, slower than a 1.5 percent increase in April. Only three of the six components contributed positively.

Stocks Close Mostly Higher Despite Afternoon Pullback - U.S. Commentary

While lingering worries about the outlook for the Federal Reserve's stimulus program generated some selling pressure in afternoon trading on Monday, stocks managed to end the day mostly higher after seeing an early rally on the heels of some upbeat economic data. The major averages finished the session well off their best levels of the day but still posted strong gains.

Poll Shows Sharp Drop In Obama's Approval Rating

In an apparent backlash from the numerous scandals facing the administration, the results of a new CNN/ORC International survey released Monday showed a sharp drop in President Barack Obama's approval rating. The poll found that 45 percent of Americans approve of the way Obama is handling his job as president, down from 53 percent in a poll conducted last month.